<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732809</url>
  </required_header>
  <id_info>
    <org_study_id>11-2011</org_study_id>
    <nct_id>NCT01732809</nct_id>
  </id_info>
  <brief_title>Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses</brief_title>
  <acronym>ABO ONA</acronym>
  <official_title>FIELDS OF EFFECTS OF TWO COMMERCIAL PREPARATIONS OF BOTULINUM TOXIN TYPE A AT EQUAL LABELED UNIT DOSES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilan Center for Studies in Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilan Center for Studies in Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the fields of effect (FE) of ABO and ONA at the same
      labeled unit dose (1:1 units), comparing both sweat gland and muscle activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-center, randomized, double-blind study. All participants will
      be recruited from a research center in Porto Alegre, Brazil, and provided written informed
      consent. This study will be approved by the local Ethics Committee of Associação Hospitalar
      Moinhos de Vento and all Good Clinical Practices, Declaration of Helsinki protocols and
      national regulations were followed. The main inclusion criteria are: female subjects aged
      between 18 to 60 years; presence of moderate to severe forehead wrinkles on both sides at
      maximum contraction of frontalis muscle according to Wrinkle Severity Scores (WSS) (Hexsel et
      al., 2012); positive sweating by the Minor's Test (Minor, 1927) and scores from III to V on
      the Sweat Intensity Visual Scale (Hexsel et al., 2010).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Field effect</measure>
    <time_frame>1 time</time_frame>
    <description>Field effect characteristics of ABO and ONA at the same dose (1:1 labeled unit equivalence) regarding both muscle and sweat gland activities.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects, Only With Wrinkles on Forehead.</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: Patients received 2units/0.02 mL of reconstituted ABO on the right side of the forehead and 2 units/0.02 mL of reconstituted ONA on the left side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group A</intervention_name>
    <description>isovolumetric (0.02 mL) doses of 2 units of ABO injected on one side of the forehead and 2 units of ONA injected on the contralateral side</description>
    <arm_group_label>group A</arm_group_label>
    <other_name>Dysport® (AbotulinumtoxinA; ABO),</other_name>
    <other_name>Botox® (OnabotulinumtoxinA; ONA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group B</intervention_name>
    <description>Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.</description>
    <arm_group_label>group B</arm_group_label>
    <other_name>Dysport® (AbotulinumtoxinA; ABO),</other_name>
    <other_name>Botox® (OnabotulinumtoxinA; ONA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female subjects aged between 18 to 60 years;

          -  presence of moderate to severe forehead wrinkles on both sides at maximum contraction
             of frontalis muscle according to Wrinkle Severity Scores (WSS) (Hexsel et al., 2012);

          -  positive sweating by the Minor's Test (Minor, 1927) and scores from III to V on the
             Sweat Intensity Visual Scale (Hexsel et al., 2010).

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris m Hexsel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CBED</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CBED</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2012</study_first_submitted>
  <study_first_submitted_qc>November 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2012</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brazilan Center for Studies in Dermatology</investigator_affiliation>
    <investigator_full_name>Doris Hexsel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>wrinkles</keyword>
  <keyword>botulinum toxin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

